Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|January 21, 2026
[CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER]Keisuke Kuretake, Akinori Minato, Shuji Harada, et al.
Journal of Colloid and Interface Science|June 29, 2014
Synthesis and characterization of anisotropically expanded graphite oxide compounds derived from spherical graphiteWenwen Zhao, Gentoku Kido, Shuji Harada, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 25, 2003
Multiple biopsies of normal-looking urothelium in patients with superficial bladder cancer: Are they necessary?Naohiro Fujimoto, Shuji Harada, Michikazu Terado, et al.
Medical Oncology (Northwood, London, England)|February 11, 2012
Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancerAkinori Minato, Naohiro Fujimoto, Tatsuhiko Kubo, et al.
Biochimica Et Biophysica Acta|April 9, 2008
Importance of the phosphocholine linkage on sphingomyelin molecular properties and interactions with cholesterol; a study with phosphate oxygen modified sphingomyelin-analoguesAnders Björkbom, Tetsuya Yamamoto, Satoshi Kaji, et al.
Cancer Investigation|March 17, 2007
Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cellsNaohiro Fujimoto, Hiroshi Miyamoto, Atsushi Mizokami, et al.
Journal of UOEH|July 13, 2004
[Screening for prostate cancer in Yahata, Kitakyushu]Naohiro Fujimoto, Shuji Harada, Hideki Sato, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 24, 2023
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumabIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Oncology Letters|November 11, 2024
Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomesIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Anticancer Research|December 30, 2022
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With PembrolizumabIkko Tomisaki, Mirii Harada, Shigeru Sakano, et al.
Pageof 2